Global Preimplantation Genetic Testing (PGD/PGS) Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

This report extensively covers different segments of Global Preimplantation Genetic Testing (PGD/PGS) Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments.

The global preimplantation genetic testing (PGT) market is witnessing a significant surge in demand owing to advancements in genetic screening technologies and increasing awareness about genetic disorders. PGT, encompassing preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS), enables the detection of genetic abnormalities in embryos prior to implantation during in vitro fertilization (IVF) procedures. The market segmentation reveals a diverse landscape, with segments based on technology, application, end user, and region. Various technologies such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH) dominate the market, each offering distinct advantages in terms of accuracy, speed, and cost-effectiveness.

In terms of applications, PGT finds extensive usage in detecting chromosomal abnormalities, single gene disorders, and structural rearrangements. Rising incidences of genetic diseases coupled with the growing trend of delayed pregnancies due to lifestyle changes contribute to the expanding application scope of PGT. Furthermore, the market segmentation by end user highlights the significance of PGT services in fertility clinics, research laboratories, and academic institutions. Fertility clinics represent the largest end-user segment due to the increasing number of IVF procedures globally and the integration of PGT services to enhance success rates and reduce the risk of genetic disorders in newborns.

Geographically, the market segmentation reflects regional variations in demand and adoption of PGT services. Developed regions such as North America and Europe dominate the market due to well-established healthcare infrastructure, high awareness levels, and favorable reimbursement policies. However, emerging economies in Asia Pacific, Latin America, and the Middle East are witnessing rapid growth attributed to improving healthcare facilities, rising disposable incomes, and increasing investments in healthcare infrastructure. The market segmentation underscores the need for continuous innovation, strategic collaborations, and regulatory compliance to capitalize on emerging opportunities and address evolving challenges in the global PGT market.

Global Preimplantation Genetic Testing (PGD/PGS) Segment Analysis

In this report, the Global Preimplantation Genetic Testing (PGD/PGS) Market has been segmented by Type, Application and Geography.

Global Preimplantation Genetic Testing (PGD/PGS) Market, Segmentation by Type

The Global Preimplantation Genetic Testing (PGD/PGS) Market has been segmented by Type into Chromosomal Abnormalities, X-linked Diseases, Freeze Embryo Testing, Aneuploidy Screening, HLA Typing and Other PGT Types.

The global Preimplantation Genetic Testing (PGD/PGS) market has witnessed substantial growth in recent years, driven by advancements in genetic testing technologies and rising demand for early detection of genetic abnormalities in embryos. PGD and PGS are techniques used during in vitro fertilization (IVF) procedures to screen embryos for genetic disorders before implantation, thereby reducing the risk of passing on inherited diseases to offspring. The market is segmented by type into PGD and PGS, each serving distinct purposes in identifying genetic abnormalities. PGD primarily focuses on detecting specific genetic disorders known to be carried by the parents, while PGS involves screening for chromosomal abnormalities, such as aneuploidy, which can lead to conditions like Down syndrome.

PGD and PGS have become integral components of assisted reproductive technology (ART) procedures, offering couples the opportunity to make informed decisions regarding embryo selection and ultimately improving the success rates of IVF treatments. The increasing prevalence of genetic disorders, coupled with growing awareness among prospective parents about the benefits of genetic testing, is expected to further propel market growth. Additionally, technological advancements, such as next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH), have enhanced the accuracy and efficiency of PGD/PGS procedures, driving adoption rates across fertility clinics worldwide.

Geographically, the global PGD/PGS market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America holds a significant share of the market, attributed to factors such as the presence of advanced healthcare infrastructure, favorable reimbursement policies, and increasing investments in research and development. However, the Asia Pacific region is poised to witness the fastest growth, driven by rising healthcare expenditure, expanding fertility tourism, and a growing emphasis on preventive healthcare measures. Key players in the market include Illumina, Inc., Thermo Fisher Scientific, Inc., Natera, Inc., and PerkinElmer, Inc., among others, who are actively involved in product development and strategic collaborations to strengthen their market presence and cater to the evolving needs of consumers in the field of reproductive genetics.

Global Preimplantation Genetic Testing (PGD/PGS) Market, Segmentation by Application

The Global Preimplantation Genetic Testing (PGD/PGS) Market has been segmented by Application into Identifying Embryo For Stem Cell Therapy, IVF Prognosis, Late Onset Genetic Disorders, Inherited Genetic Disease and Others.

The global Preimplantation Genetic Testing (PGT) market, which encompasses both Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS), has been experiencing significant growth due to advancements in assisted reproductive technology and rising awareness regarding genetic disorders. PGT involves the screening of embryos for genetic abnormalities before implantation, thus helping couples undergoing in vitro fertilization (IVF) to select healthy embryos for transfer, thereby reducing the risk of genetic diseases in offspring. The market segmentation by application highlights its widespread utility across various genetic conditions, including chromosomal abnormalities, single gene disorders, and structural rearrangements, catering to the diverse needs of individuals seeking fertility treatments.

PGT's applications span across several areas, with chromosomal abnormality screening being a prominent segment in the market. This involves the detection of numerical abnormalities, such as aneuploidy, which are common causes of implantation failure, miscarriages, and genetic disorders like Down syndrome. Additionally, PGT facilitates the screening of single gene disorders, enabling the identification of mutations responsible for conditions like cystic fibrosis, sickle cell anemia, and Huntington's disease. Such targeted screening ensures that couples with a family history of genetic disorders can make informed decisions about embryo selection, ultimately reducing the incidence of hereditary diseases in their offspring.

The segmentation of the PGT market extends to structural rearrangements, addressing concerns related to balanced translocations, inversions, and other chromosomal rearrangements that may lead to infertility or recurrent miscarriages. By offering insights into the genetic integrity of embryos, PGT enhances the success rates of IVF procedures and minimizes the emotional and financial burden associated with multiple failed attempts. With the increasing demand for personalized reproductive medicine and the expanding scope of genetic testing technologies, the global PGT market is poised for continued growth, driven by the imperative to deliver healthier outcomes for families worldwide.

Global Preimplantation Genetic Testing (PGD/PGS) Market, Segmentation by Geography

In this report, the Global Preimplantation Genetic Testing (PGD/PGS) Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Preimplantation Genetic Testing (PGD/PGS) Market Share (%), by Geographical Region, 2024

In North America, particularly in the United States and Canada, the market holds a significant share. Factors such as advanced healthcare infrastructure, high adoption rates of assisted reproductive technologies (ART), and favorable reimbursement policies contribute to the region's dominance. Key players in the North American PGT market include Illumina, Inc., Natera, Inc., and Thermo Fisher Scientific Inc.

Europe is another major market for PGT, with countries like the United Kingdom, Germany, France, and Spain leading in terms of adoption. Increasing awareness about genetic disorders, coupled with supportive government initiatives, drives the growth of the PGT market in Europe. Companies such as Oxford Gene Technology, CooperSurgical, Inc., and Eurofins Scientific are prominent players in this region.

The Asia Pacific region is witnessing rapid growth in the PGT market, driven by factors such as rising infertility rates, increasing disposable income, and improving healthcare infrastructure. Countries like China, India, Japan, and Australia are significant contributors to the market's expansion in this region. Local players, along with international companies like BGI Group, are actively involved in catering to the growing demand for PGT services.

In the Middle East and Africa (MEA) region, there is a gradual uptake of PGT services, primarily driven by improving healthcare facilities and increasing awareness about genetic disorders. Countries such as the United Arab Emirates, Saudi Arabia, and South Africa are witnessing the adoption of PGT techniques in fertility clinics. Although still emerging, the MEA market presents growth opportunities for companies like Igenomix and Fertility Road Magazine.

Latin America represents a growing market for PGT, fueled by factors such as expanding medical tourism, rising infertility rates, and increasing healthcare expenditure. Brazil, Mexico, Argentina, and Colombia are among the key countries driving the demand for PGT services in the region. Companies like Genesis Genetics, Invicta Fertility Clinic, and Genoma Lab Internacional are active participants in the Latin American PGT market.

This report provides an in depth analysis of various factors that impact the dynamics of Global Preimplantation Genetic Testing (PGD/PGS) Market. These factors include; Market Drivers, Restraints and Opportunities Analysis,

Drivers, Restraints and Opportunity Analysis

Drivers

• Advancements in Technology
• Rising Prevalence of Genetic Disorders
• Growing Adoption of Assisted Reproductive Technologies (ART)

• Increasing Focus on Healthy Pregnancy - There has been a significant surge in the global preimplantation genetic testing (PGT) market, fueled by an increasing emphasis on ensuring healthy pregnancies. PGT, encompassing both preimplantation genetic diagnosis (PGD) and preimplantation genetic screening (PGS), offers prospective parents the opportunity to assess embryos for genetic abnormalities before implantation during in vitro fertilization (IVF) procedures. This technology has garnered attention for its potential to mitigate the risk of transmitting inherited genetic disorders to offspring, thus promoting the birth of healthy babies.

  One of the primary drivers behind the growing adoption of PGT is the rising awareness among couples about the role of genetic factors in pregnancy outcomes. With advancements in medical knowledge and increased accessibility to genetic testing, more individuals are seeking proactive measures to reduce the likelihood of passing on hereditary conditions to their children. This proactive approach aligns with the broader trend of prioritizing preventive healthcare strategies, where early intervention through PGT empowers prospective parents to make informed decisions about their reproductive choices.

  The expanding scope of PGT technologies, coupled with advancements in genomic analysis techniques, has bolstered the market's growth trajectory. Innovations such as next-generation sequencing (NGS) have enhanced the accuracy and efficiency of genetic screening, enabling healthcare providers to detect a wider range of genetic anomalies with greater precision. As a result, PGT has evolved from being primarily utilized for detecting single-gene disorders to encompassing comprehensive chromosomal screening, thereby catering to a broader spectrum of genetic concerns and increasing its appeal to a wider demographic of prospective parents.

  Regulatory initiatives and supportive policies aimed at promoting accessibility to assisted reproductive technologies (ART) have contributed to the market expansion. Governments and healthcare authorities worldwide are recognizing the importance of reproductive health and are taking steps to address barriers to accessing fertility treatments, including PGT. Additionally, collaborations between healthcare providers, genetic laboratories, and IVF clinics are fostering innovation and driving down costs associated with PGT procedures, making them more accessible to a larger population. As the global focus on healthy pregnancies intensifies, the PGT market is poised for sustained growth, offering hope to millions of individuals striving to build families while minimizing the risk of hereditary diseases.

Restraints

• Regulatory hurdles
• Ethical considerations
• Limited access to advanced technologies

• High costs associated with testing - PGD/PGS require advanced laboratory facilities equipped with sophisticated instrumentation and highly trained personnel. The complexity of these techniques translates into substantial operational costs, including equipment maintenance, consumables, and staff salaries. Moreover, stringent quality control measures are imperative to ensure the accuracy and reliability of test results, further escalating expenses.

  Regulatory frameworks governing reproductive genetics necessitate adherence to stringent standards and protocols, adding another layer of expense. Laboratories offering PGD/PGS must comply with regulatory requirements imposed by authorities such as the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe. Acquiring and maintaining accreditation from relevant regulatory bodies entail considerable financial investments, contributing to the overall cost burden.

  Despite the medical necessity of PGD/PGS for individuals at risk of transmitting genetic disorders or experiencing recurrent pregnancy loss, insurance coverage remains limited. Many insurance providers classify these procedures as elective or experimental, offering minimal or no reimbursement for associated expenses. Consequently, individuals undergoing PGD/PGS often bear the brunt of costs out-of-pocket, straining financial resources and posing barriers to access for economically disadvantaged patients.

  The cumulative effect of these factors results in exorbitant costs associated with PGD/PGS testing, rendering it financially prohibitive for a significant portion of the population. Addressing affordability concerns necessitates concerted efforts from stakeholders across the healthcare spectrum, including policymakers, insurers, and industry players, to facilitate equitable access to these indispensable genetic screening technologies.

Opportunities

• Technological Advancements
• Rising Demand for Assisted Reproductive Technologies (ART)
• Growing Awareness and Acceptance

• Expanding Applications - Preimplantation Genetic Testing (PGT), including both Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS), has witnessed significant expansion in its applications, driving growth in the global market. Firstly, PGT has become increasingly utilized in assisted reproductive technology (ART) procedures to screen embryos for genetic abnormalities before implantation, thereby reducing the risk of transmitting hereditary diseases to offspring. This application is particularly crucial for couples with a family history of genetic disorders, providing them with the opportunity to select embryos free from these conditions, ultimately improving the chances of having a healthy baby.

  The scope of PGT has extended beyond genetic disease screening to include broader applications in fertility treatment. PGS, in particular, has gained traction for assessing embryo chromosomal abnormalities, aiding in the selection of embryos with the highest probability of successful implantation and reducing the likelihood of miscarriage during in vitro fertilization (IVF) procedures. This expanded application has contributed to the growing adoption of PGT techniques in fertility clinics worldwide, as they strive to enhance pregnancy outcomes and minimize reproductive risks for patients undergoing ART.

  Advancements in genomic technologies and the introduction of next-generation sequencing (NGS) have further propelled the expansion of PGT applications. NGS allows for comprehensive genetic analysis, enabling the simultaneous screening of multiple genetic abnormalities with high accuracy and efficiency. As a result, PGT has evolved to encompass the detection of aneuploidy, single gene disorders, and chromosomal structural rearrangements, catering to a wider range of patient needs and preferences. With ongoing research and development efforts aimed at refining PGT techniques and expanding its clinical utility, the global market for preimplantation genetic testing is poised for continued growth, driven by its expanding applications in reproductive medicine and assisted fertility treatments.

Key players in Global Preimplantation Genetic Testing (PGD/PGS) Market include,

• F. Hoffmann-La Roche AG
• Genea Limited
• Quest Diagnostics
• Illumina, Inc.
• Natera, Inc.
• CooperSurgical, Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• California Pacific Medical Center (CPMC)
• Thermo Fisher Scientific Inc.
• Igenomix

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis